Filtered Trial for Telmisartan 40mg Non-responder
Primary Purpose
Hypertension
Status
Completed
Phase
Phase 3
Locations
Japan
Study Type
Interventional
Intervention
telmisartan+amlodipine
telmisartan
Sponsored by

About this trial
This is an interventional treatment trial for Hypertension
Eligibility Criteria
Inclusion Criteria:
- Essential hypertensive patients who satisfying non-responder criteria
- Male or Female
- Age 20 years or older
- Outpatient
Exclusion Criteria:
- Taking four or more anti-hypertensive medications
- Secondary hypertension
- Mean seated diastolic blood pressure (DBP) > 114 mmHg and/or mean seated systolic blood pressure (SBP) > 200 mmHg at Visit 1, 2, 3, or 4, or mean seated DBP < 90 mmHg at Visit 3.
- Sustained ventricular tachycardia or other clinically relevant cardiac arrhythmias
- Congestive heart failure patients with the New York Heart Association (NYHA) functional class III-IV
- History of myocardial infarction or cardiac surgery within last 6 months
- History of coronary artery bypass graft or percutaneous coronary intervention (PCI) within last 3 months
- History of unstable angina within last 3 months
- Hypertrophic obstructive cardiomyopathy, aortic stenosis, hemodynamically relevant stenosis of aortic or mitral valve
- History of stroke or transient ischemic attack within last 6 months
- History of sudden exacerbation of renal function with angiotensin II receptor blockers (ARBs) or angiotensin converting enzyme (ACE) inhibitors, or patients with post-renal transplant or post-nephrectomy
- Experienced characteristic symptoms of angioedema during treatment with ARBs or ACE inhibitors
- Known hypersensitivity to any component of the investigational drug , or a known hypersensitivity to dihydropyridine -derived drugs
- Hepatic and/or renal dysfunction
- Diagnosed biliary atresia or cholestasis
- Hyperkalemia
- Dehydration
- Sodium deficiency
- Chronic administration of high doses of acidic nonsteroidal anti-inflammatory drugs (NSAIDs)
- Patients who cannot change to the restricted administration and dosage during study period
Pre-menopausal women who meet any one of the following 1 - 3:
- Pregnant or possibly pregnant (1)
- Nursing (2)
- Desire to become pregnant during study period (3)
- Drug or alcohol dependency
- Complication of malignant tumour or a disease requiring immunosuppressants
- Compliance of < 80% or > 120% during the run-in period
- Receiving any investigational therapy within 3 months
- Judged to be inappropriate by the investigator or the sub-investigator
Sites / Locations
- 1235.14.002 Boehringer Ingelheim Investigational Site
- 1235.14.003 Boehringer Ingelheim Investigational Site
- 1235.14.005 Boehringer Ingelheim Investigational Site
- 1235.14.004 Boehringer Ingelheim Investigational Site
- 1235.14.001 Boehringer Ingelheim Investigational Site
Outcomes
Primary Outcome Measures
Decrease in Seated Diastolic Blood Pressure From Baseline to 8 Weeks
The mean of the change value was least square mean which was calculated by analysis of covariance with factor treatment and center, and covariate baseline.
Secondary Outcome Measures
Decrease in Seated Systolic Blood Pressure From Baseline to 8 Weeks
The mean of the change value was least square mean which was calculated by analysis of covariance with factor treatment and center, and covariate baseline.
Percentage of Patients With Seated Trough Diastolic Blood Pressure Less Than 90 mmHg at 8 Weeks (0 Percent at Baseline)
Seated trough diastolic blood pressure defined as blood pressure in a sitting position no later than 24 hours after the last intake
Percentage of Patients With Seated Trough Systolic Blood Pressure Less Than 140 mmHg at 8 Weeks (0 Percent at Baseline)
Seated trough systolic blood pressure defined as blood pressure in a sitting position no later than 24 hours after the last intake
Percentage of Patients Who Achieved an Adequate Response in Seated Trough Diastolic Blood Pressure at 8 Weeks (0 Percent at Baseline)
Adequate response defined that seated trough diastolic blood pressure was <90 mmHg or decreased from reference baseline by >=10 mmHg at 8 weeks
Percentage of Patients Who Achieved an Adequate Response in Seated Trough Systolic Blood Pressure at 8 Weeks (0 Percent at Baseline)
Adequate response defined that seated trough systolic blood pressure was <140 mmHg or decreased from reference baseline by >=20 mmHg at 8 weeks (0 percent at baseline)
Percentage of Patients With Optimal, Normal or High Normal Blood Pressure at 8 Weeks (0 Percent at Baseline)
Optimal, normal, high normal blood pressure were defined as follows:
Optimal: Systolic blood pressure (SBP) < 120 mmHg and diastolic blood pressure (DBP) < 80 mmHg
Normal: SBP >= 120 mmHg or DBP >= 80 mmHg and SBP < 130 mmHg and DBP < 85 mmHg
High normal: SBP >= 130 mmHg or DBP >= 85 mmHg and SBP < 140 mmHg and DBP < 90 mmHg
Clinically Relevant Abnormalities for Changes in Blood Pressure and Pulse Rate Due to Position Change, Seated Pulse Rate, Laboratory Parameters and ECG
Clinical relevant abnormalities for changes in blood pressure and pulse rate due to position change, seated pulse rate, laboratory parameters and ECG. New abnormal findings or worsening of baseline conditions were reported as Adverse Events.
Full Information
NCT ID
NCT00550953
First Posted
October 26, 2007
Last Updated
December 12, 2013
Sponsor
Boehringer Ingelheim
1. Study Identification
Unique Protocol Identification Number
NCT00550953
Brief Title
Filtered Trial for Telmisartan 40mg Non-responder
Official Title
Filtered Trial for Telmisartan 40mg Non-responder
Study Type
Interventional
2. Study Status
Record Verification Date
December 2013
Overall Recruitment Status
Completed
Study Start Date
October 2007 (undefined)
Primary Completion Date
July 2008 (Actual)
Study Completion Date
undefined (undefined)
3. Sponsor/Collaborators
Name of the Sponsor
Boehringer Ingelheim
4. Oversight
5. Study Description
Brief Summary
The primary purpose of this study is to:
Demonstrate that a fixed-dose combination of telmisartan 40 mg plus amlodipine 5 mg is superior to telmisartan 40 mg alone in patients with essential hypertension and inadequately controlled with telmisartan 40 mg monotherapy.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Enrollment
314 (Actual)
8. Arms, Groups, and Interventions
Intervention Type
Drug
Intervention Name(s)
telmisartan+amlodipine
Intervention Type
Drug
Intervention Name(s)
telmisartan
Primary Outcome Measure Information:
Title
Decrease in Seated Diastolic Blood Pressure From Baseline to 8 Weeks
Description
The mean of the change value was least square mean which was calculated by analysis of covariance with factor treatment and center, and covariate baseline.
Time Frame
Baseline and 8 Weeks
Secondary Outcome Measure Information:
Title
Decrease in Seated Systolic Blood Pressure From Baseline to 8 Weeks
Description
The mean of the change value was least square mean which was calculated by analysis of covariance with factor treatment and center, and covariate baseline.
Time Frame
Baseline and 8 weeks
Title
Percentage of Patients With Seated Trough Diastolic Blood Pressure Less Than 90 mmHg at 8 Weeks (0 Percent at Baseline)
Description
Seated trough diastolic blood pressure defined as blood pressure in a sitting position no later than 24 hours after the last intake
Time Frame
8 weeks
Title
Percentage of Patients With Seated Trough Systolic Blood Pressure Less Than 140 mmHg at 8 Weeks (0 Percent at Baseline)
Description
Seated trough systolic blood pressure defined as blood pressure in a sitting position no later than 24 hours after the last intake
Time Frame
8 weeks
Title
Percentage of Patients Who Achieved an Adequate Response in Seated Trough Diastolic Blood Pressure at 8 Weeks (0 Percent at Baseline)
Description
Adequate response defined that seated trough diastolic blood pressure was <90 mmHg or decreased from reference baseline by >=10 mmHg at 8 weeks
Time Frame
8 weeks
Title
Percentage of Patients Who Achieved an Adequate Response in Seated Trough Systolic Blood Pressure at 8 Weeks (0 Percent at Baseline)
Description
Adequate response defined that seated trough systolic blood pressure was <140 mmHg or decreased from reference baseline by >=20 mmHg at 8 weeks (0 percent at baseline)
Time Frame
8 weeks
Title
Percentage of Patients With Optimal, Normal or High Normal Blood Pressure at 8 Weeks (0 Percent at Baseline)
Description
Optimal, normal, high normal blood pressure were defined as follows:
Optimal: Systolic blood pressure (SBP) < 120 mmHg and diastolic blood pressure (DBP) < 80 mmHg
Normal: SBP >= 120 mmHg or DBP >= 80 mmHg and SBP < 130 mmHg and DBP < 85 mmHg
High normal: SBP >= 130 mmHg or DBP >= 85 mmHg and SBP < 140 mmHg and DBP < 90 mmHg
Time Frame
8 weeks
Title
Clinically Relevant Abnormalities for Changes in Blood Pressure and Pulse Rate Due to Position Change, Seated Pulse Rate, Laboratory Parameters and ECG
Description
Clinical relevant abnormalities for changes in blood pressure and pulse rate due to position change, seated pulse rate, laboratory parameters and ECG. New abnormal findings or worsening of baseline conditions were reported as Adverse Events.
Time Frame
First administration of randomised treatment to 24 hours post last dose of randomised treatment
10. Eligibility
Sex
All
Minimum Age & Unit of Time
20 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Essential hypertensive patients who satisfying non-responder criteria
Male or Female
Age 20 years or older
Outpatient
Exclusion Criteria:
Taking four or more anti-hypertensive medications
Secondary hypertension
Mean seated diastolic blood pressure (DBP) > 114 mmHg and/or mean seated systolic blood pressure (SBP) > 200 mmHg at Visit 1, 2, 3, or 4, or mean seated DBP < 90 mmHg at Visit 3.
Sustained ventricular tachycardia or other clinically relevant cardiac arrhythmias
Congestive heart failure patients with the New York Heart Association (NYHA) functional class III-IV
History of myocardial infarction or cardiac surgery within last 6 months
History of coronary artery bypass graft or percutaneous coronary intervention (PCI) within last 3 months
History of unstable angina within last 3 months
Hypertrophic obstructive cardiomyopathy, aortic stenosis, hemodynamically relevant stenosis of aortic or mitral valve
History of stroke or transient ischemic attack within last 6 months
History of sudden exacerbation of renal function with angiotensin II receptor blockers (ARBs) or angiotensin converting enzyme (ACE) inhibitors, or patients with post-renal transplant or post-nephrectomy
Experienced characteristic symptoms of angioedema during treatment with ARBs or ACE inhibitors
Known hypersensitivity to any component of the investigational drug , or a known hypersensitivity to dihydropyridine -derived drugs
Hepatic and/or renal dysfunction
Diagnosed biliary atresia or cholestasis
Hyperkalemia
Dehydration
Sodium deficiency
Chronic administration of high doses of acidic nonsteroidal anti-inflammatory drugs (NSAIDs)
Patients who cannot change to the restricted administration and dosage during study period
Pre-menopausal women who meet any one of the following 1 - 3:
Pregnant or possibly pregnant (1)
Nursing (2)
Desire to become pregnant during study period (3)
Drug or alcohol dependency
Complication of malignant tumour or a disease requiring immunosuppressants
Compliance of < 80% or > 120% during the run-in period
Receiving any investigational therapy within 3 months
Judged to be inappropriate by the investigator or the sub-investigator
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Boehringer Ingelheim
Organizational Affiliation
Boehringer Ingelheim
Official's Role
Study Chair
Facility Information:
Facility Name
1235.14.002 Boehringer Ingelheim Investigational Site
City
Chofu, Tokyo
Country
Japan
Facility Name
1235.14.003 Boehringer Ingelheim Investigational Site
City
Musashino, Tokyo
Country
Japan
Facility Name
1235.14.005 Boehringer Ingelheim Investigational Site
City
Nishi-ku, Hiroshima, Hiroshima
Country
Japan
Facility Name
1235.14.004 Boehringer Ingelheim Investigational Site
City
Osaka, Osaka
Country
Japan
Facility Name
1235.14.001 Boehringer Ingelheim Investigational Site
City
Shinjuku-ku, Tokyo
Country
Japan
12. IPD Sharing Statement
Links:
URL
http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/1235/1235.14_U09-3883.pdf
Description
Related Info
Learn more about this trial
Filtered Trial for Telmisartan 40mg Non-responder
We'll reach out to this number within 24 hrs